SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

PRODUCT INFORMATION

Atazanavir-d_6

Item No. 26456

CAS Registry No.: 1092540-50-5
Formal Name: (3S,8S,9S,12S)-3,12-*bis*(1,1-dimethylethyl)-8-hydroxy-4,11-dioxo-9-(phenylmethyl)-6-[[4-(2-pyridinyl)phenyl]methyl]-2,5,6,10,13-pentaazatetradecanedioic acid, 1,14-di(methyl-d_3) ester
MF: $C_{38}H_{46}D_6N_6O_7$
FW: 710.9
Chemical Purity: ≥98% (Atazanavir)
Deuterium Incorporation: ≥99% deuterated forms (d_1-d_6); ≤1% d_0
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Atazanavir-d_6 is intended for use as an internal standard for the quantification of atazanavir (Item No. 11733) by GC- or LC-MS. The accuracy of the sample weight in this vial is between 5% over and 2% under the amount shown on the vial. If better precision is required, the deuterated standard should be quantitated against a more precisely weighed unlabeled standard by constructing a standard curve of peak intensity ratios (deuterated *versus* unlabeled).

Atazanavir-d_6 is supplied as a solid. A stock solution may be made by dissolving the atazanavir-d_6 in the solvent of choice, which should be purged with an inert gas. Atazanavir-d_6 is slightly soluble in organic solvents such as ethanol and methanol.

Description

Atazanavir is an azapeptide inhibitor of HIV-1 protease (K_i = 2.66 nM).[1] It has antiviral activity against a variety of HIV-1 strains in several cell types with EC_{50} values ranging from 2.62 to 5.28 nM. Atazanavir exhibits a minor synergistic effect when used in combination with the reverse transcriptase inhibitor zidovudine (Item No. 15492) in HIV-1-infected human peripheral blood mononuclear cells (PBMCs) and an additive effect when used in combination with several additional reverse transcriptase or HIV-1 protease inhibitors. Atazanavir also inhibits UDP-glucuronyltransferase 1A1 (UGT1A1), which is involved in bilirubin clearance.[2] Formulations containing atazanavir have been used in combination therapy for the treatment of HIV-1 infection.

References

1. Robinson, B.S., Riccardi, K.A., Gong, Y.F., *et al.* BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents. *Antimicrob. Agents Chemother.* **44(8)**, 2093-2099 (2000).
2. Michaud, V., Bar-Magen, T., Turgeon, J., *et al.* The dual role of pharmacogenetics in HIV treatment: Mutations and polymorphisms regulating antiretroviral drug resistance and disposition. *Pharmacol. Rev.* **64(3)**, 803-833 (2012).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM